Hadassah University Hospital is currently recruiting patients with the retinal disease, Dry AMD (dry form of age-related macular degeneration) for a clinical trial of a novel cell therapy product, OpRegen®, developed by Cell Cure Neurosciences Ltd. in cooperation with the hospital. The purpose of this first-in-humans study is to evaluate the safety and to explore the efficacy of OpRegen in treatment of Dry AMD. In order to participate in the study, the patient should be at least 55 years old, in good health, should have been diagnosed with dry AMD/ geographic atrophy, but with no history of wet AMD, and a visual acuity worse than 20/200. The patients will need to be available for frequent follow-up for 12 months in Israel. No direct benefits to the patient can be promised.
Further information about the trial can be found at https://www.clinicaltrials.gov/ct2/show/NCT02286089 and via email: email@example.com.